TNYA — Tenaya Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1858848 ·
Last close
$0.61
Market Cap
$136.78M
52W High
$2.35
52W Low
$0.53
ADV30
2,151,253
Next earnings
2026-11-11

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,110,000 — -20,899,000 -43,393,000 93,540,000 78,085,000 24,131,000
Mar 2026 225,000 — -20,065,000 -19,272,000 135,070,000 80,887,000 28,881,000
Dec 2025 0 — -20,775,000 -20,175,000 146,921,000 100,547,000 23,656,000
Sep 2025 0 — -20,936,000 -20,275,000 104,980,000 56,312,000 22,112,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-52,325,000
Investing CF
$8,623,000
Financing CF
$59,116,000
CapEx
$-263,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.53
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-667,673,000
Inventory
—
Receivables
$371,000
ST Investments
$0
EBIT TTM
$-82,675,000
Pretax Income TTM
$-103,115,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,335,000
EBITDA
$-75,524,000
Free Cash Flow
$-32,600,500
Enterprise Value
$69,371,208
Total Cash
$78,085,000
Total Debt
$3,949,000
Shares Out
224,230,012
Trailing EPS
$-0.51
Book Value
$0.49
ROE
-121.9%
ROA
-47.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -93,331,000 -90,597,000 146,921,000 23,656,000 123,265,000 -68,264,000
Dec 2024 0 -115,948,000 -111,129,000 119,940,000 27,086,000 92,854,000 -90,501,000
Dec 2023 0 -131,193,000 -124,084,000 170,515,000 31,091,000 139,424,000 -102,072,000
Dec 2022 0 -125,621,000 -123,665,000 278,945,000 35,569,000 243,376,000 -104,424,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.39

Max Pain — expiry 2026-10-16

max pain strike: $0.50 · spot: $0.60 · call oi: 2,965 · put oi: 392
Expected Move to 2026-10-16: ±$0.20 (33.48%) — implied range $0.40 – $0.80 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ARMP Armata Pharmaceuticals, Inc. $139.06M $3.74 —
CRBU Caribou Biosciences, Inc. $132.94M $1.24 —
ENGN enGene Therapeutics Inc. $131.35M $1.96 —
NMRA Neumora Therapeutics, Inc. $127.39M $0.68 —
LENZ LENZ Therapeutics, Inc. $123.01M $3.91 —

News headlines (Yahoo Finance, 1h cache)

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
2026-09-14 12:30 · Yahoo
Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck
2026-09-10 13:56 · Yahoo
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-03 20:30 · Yahoo
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
2026-08-18 08:01 · Yahoo
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05 20:05 · Yahoo
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-15 01:00 · Yahoo
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
2026-06-29 12:30 · Yahoo
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sympt
2026-06-03 11:00 · Yahoo
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
2026-06-02 20:30 · Yahoo
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
2026-05-29 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.